Barbra Weiss

Regulatory Liaison with 13 years years of experience in Oncology in International Markets, and total over 25 years in scientific/pharmaceutical industry with strong background in fostering communication and building relationships. Skilled in team collaboration and adept at navigating changing needs to achieve results. Expertise in conflict resolution, project management, and strategic planning. Reliable, adaptable, and focused on driving success through effective partnerships and clear communication.

• National Certification Agency- Certified Laboratory Scientist (Aug 1999)
• American Society of Clinical Pathologists-Certified Medical Technologist (Aug 1999)

• WEISS, B.N., TANEN, M.R., SAMATAR, A., STRACK, P.R., LATERZA, O.F., WEINER, R. Fit for purpose validation of Phosphorylated Extracellular Signal-Regulated Kinase (perk) Assay in ex-vivo PMA Stimulated Human Whole Blood and Hair Follicles. American Association Of Pharmaceutical Scientists 2011 Annual Meeting And Exposition (AAPS), Washington DC, 10/23/11 - 10/27/11
• CHAPPELL, D.L.* , MCAVOY, T.A., WEISS, B.N., LATERZA, O.F. Fit-for-purpose validation of an lc/ms/ms plasma renin activity assay. American Association Of Pharmaceutical Scientists 2011 Annual Meeting And Exposition (AAPS), Washington DC, 10/23/11-10/27/11
• LATERZA, O., TANEN, M., NATASHA, T., PICA-MENDEZ, A., WEISS, B., CHAPPELL, D., KURTZ, M., HAILMAN, E., WAGNER, J., TANAKA, W. Analytical Validation of Multiplexed Immunoassays for the Quantitaion of Biomarkers in Atherosclerotic Plaques. Merck Target Through 2b Symposium. 2008.
• TANEN, M.R., WEISS, B.N., PICA-MENDEZ, A.M., LOUGHNEY, J.W., CHAPPELL, D.L., LAZAR, G., NATASHA, T., KURTZ, M.M., HAILMAN, E.P., TANAKA, W.K., LATERZA,O.F.* Validation of multiplexed immunoassays for the analysis of putative markers of coronary artery disease (cad) in atherosclerotic plaque. American Association For Clinical Chemistry Annual Meeting (AACC), Washington DC, 7/27/08 - 7/31/08
• LAZAR, G.., LATERZA, O., TANEN, M., LOUGHNEY, J., NATASHA, T., PICA-MENDEZ, A., WEISS, B., CHAPPELL, D., KURTZ, M., HAILMAN, E., WAGNER, J., DALLOB, A., TANAKA, W. Analytical validation of multiplexed immunoassays for the quantitation of biomarkers in atherosclerotic plaques.Merck Technology Symposium. Long Branch, NJ. May 2008.
• TANEN, M., CHAPPELL, D., WEISS, B., PLUMP, A., TANAKA, W., LATERZA, O. Mesoscale Discovery Multiplex Assay for Use in Clinical Biomarker Development. Merck Technology Symposium. Long Branch, NJ. May 2006.
• KOPNITSKY, M.J., LANGER, B.. Use of SeraSub as a Serum Diluent in the Manufacturing of ELISA Controls. AACC Conference, July 2001
• "Dipeptidyl Peptidase-4 Inhibitors Administered in Combination with Metformin result in an Additive Increase in the Plasma Concentration of Active GLP-1" EM Migoya, R. Bergeron, JL Miller, M Tanen, D. Hilliard, B Weiss, P Larson, M Guterierez, G. Jiang, F Liu, KA Pryor, J Yao, L Zhu, JJ Hoist, C Deacon, G Herman, N Thornberry, J Amatruda, D Williams-herman, JA Wagner, and R SinhaRoy. Clinical Pharmacology & Therapeutics. (2010) 88 6, 801-808.
• “Development and validation of an ultra-sensitive method for the measurement of plasma renin activity in human plasma via LC–MS/MS” Derek L Chappell, Thomas McAvoy, Barbra Weiss, Russell Weiner, Omar F Laterza. Bioanalysis, December 2012, Vol. 4, No. 23, Pages 2843-2850.